Skyworks, elf Beauty, and Newell Brands Are on Sale
In the last week, three stocks fell fast enough that their shares are now on sale.Skyworks Solutions (SWKS) lost 22.4% of its value after posting fiscal first-quarter earnings. The chip supplier to Apple reported revenue falling by 10.8% Y/Y to $1.07 billion. Although it secured 5G content deals for Android suppliers (Samsung, Xiaomi, and Asus), investors sold SWKS stock.For Q2, Skyworks expects revenue and EPS to meet consensus estimates. However, CFO Kris Sennesael is anticipating a mid-to-high teens sequential decline in the mobile market. To support shareholders, the firm approved a new $2 billion stock buyback program.elf Beauty (ELF) lost one-quarter of its value last week, closing at $71.13. The beauty supplier now expects a 27-28% Y/Y increase in net sales, down from 28-30% previously. The company started experiencing weaker sales in December. Promotions started to lose their effectiveness.The over 20% yearly growth and modest valuation make ELF stock a buyout candidate.Newell Brands (NWL) dropped by 26.42% on Feb. 7 after posting Q4 revenue of $1.95 billion. This year, revenue will fall again for the eighth time out of the last nine years.NWL stock has an attractive EBITDA multiple. If Newell reports flat core sales this year, the stock might rally back to $10.00. Newell closed at $7.13.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


